ST Pharm announced on October 31 that it participated in the world's largest pharmaceutical exhibition, 'CPHI Worldwide 2025,' held in Frankfurt, Germany from October 28 to 30 (local time), where it actively promoted its main business, oligonucleotide CDMO (Contract Development and Manufacturing Organization).
Prior to the event, more than 50 pre-meeting reservations were requested with ST Pharm, and numerous business meetings were also held onsite, serving as an opportunity to reaffirm ST Pharm's global presence as a CDMO company.
This year, ST Pharm completed and began full-scale operation of its second oligonucleotide facility to enhance its ability to respond to global orders. The second facility is equipped with both small-to-medium and large-scale production lines, enabling the company to respond proactively to client needs from early clinical stages to commercialization.
Based on its production capabilities and globally recognized quality, ST Pharm expects to attract new clients through CPHI. In addition, at the CPHI venue, the company met with clients in the small molecule API sector to review the status of ongoing projects and discuss business expansion opportunities.
Since 2016, ST Pharm has been showcasing its presence in the global pharmaceutical market by producing a dedicated booth in collaboration with Dong-A ST every year.
A representative from ST Pharm stated, "Our participation in CPHI Worldwide has further solidified ST Pharm's status as a global K-Bio CDMO," and added, "We plan to further strengthen collaboration with global partners based on our RNA-based innovative technologies and CDMO capabilities."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
